Tags

Type your tag names separated by a space and hit enter

The immunotherapy with hMASP-2 DNA nanolipoplexes against echinococcosis in experimentally protoscolex-infected mice.
Acta Trop. 2020 Jun 12; 210:105579.AT

Abstract

Cystic echinococcosis (CE), a complex and neglected zoonotic infectious disease, is mainly caused by larval tapeworm Echinococcus granulosus with a worldwide distribution. For CE, an effective drug treatment is not yet available. The present study was conducted to evaluate the efficacy of hMASP-2-based immunotherapy against hydatid cysts by using murine model. Eighteen weeks after infection with 2000 viable protoscoleces intraperitoneally, the infected mice were treated with hMASP-2 DNA nanolipoplexes (pcDNA3.1-hMASP-2) and albendazole respectively. After six weeks treatment, a significant reduction in the weight of cysts was observed both in the pcDNA3.1-hMASP-2 group and albendazole group compared with the untreated group (P < 0.05). The hMASP-2 DNA nanolipoplexes not only inhibited the development of germinal layer, but also induced the extensive degeneration and damage of the germinal layer cells. Furthermore, compared with the untreated group, the number of CD4+T cells and CD8+T cells and the level of serum IFN-γ were significantly increased (P < 0.05). The frequency of PD-1+T-cell subpopulations including CD4+PD-1+T cells and CD8+PD-1+T cells and the level of serum IL-4 were notably decreased (P < 0.05) in the pcDNA3.1-hMASP-2 treatment group. Therefore, the hMASP-2 DNA nanolipoplexes displayed an effective treatment for echinococcosis through inhibiting the development of cysts and up-regulatory T-cell immunity. This new hMASP-2-based immunotherapeutic strategy could be a potential alternative for the treatment of CE, but further studies are recommended to evaluate the full potential of these hMASP-2 DNA nanolipoplexes in the treatment of human CE.

Authors+Show Affiliations

Department of Immunology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.Department of Immunology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.Department of Immunology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.Department of Immunology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.Department of Immunology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.Department of Immunology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.Department of Immunology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.Department of Immunology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.Department of Immunology, Medical College, Northwest Minzu University, Lanzhou, 730030, China.Department of Immunology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China; Key Lab of Preclinical Study for New Drugs of Gansu Province, Lanzhou, 730000, China. Electronic address: maxm@lzu.edu.cn.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32535067

Citation

Chen, Chong, et al. "The Immunotherapy With hMASP-2 DNA Nanolipoplexes Against Echinococcosis in Experimentally Protoscolex-infected Mice." Acta Tropica, vol. 210, 2020, p. 105579.
Chen C, Gao Q, Luo Y, et al. The immunotherapy with hMASP-2 DNA nanolipoplexes against echinococcosis in experimentally protoscolex-infected mice. Acta Trop. 2020;210:105579.
Chen, C., Gao, Q., Luo, Y., Zhang, G., Xu, X., Li, Z., Wang, J., He, Q., Sheng, L., & Ma, X. (2020). The immunotherapy with hMASP-2 DNA nanolipoplexes against echinococcosis in experimentally protoscolex-infected mice. Acta Tropica, 210, 105579. https://doi.org/10.1016/j.actatropica.2020.105579
Chen C, et al. The Immunotherapy With hMASP-2 DNA Nanolipoplexes Against Echinococcosis in Experimentally Protoscolex-infected Mice. Acta Trop. 2020 Jun 12;210:105579. PubMed PMID: 32535067.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The immunotherapy with hMASP-2 DNA nanolipoplexes against echinococcosis in experimentally protoscolex-infected mice. AU - Chen,Chong, AU - Gao,Qi, AU - Luo,Yanping, AU - Zhang,Guochao, AU - Xu,Xiaoying, AU - Li,Zhi, AU - Wang,Jianghua, AU - He,Qi, AU - Sheng,Li, AU - Ma,Xingming, Y1 - 2020/06/12/ PY - 2019/12/11/received PY - 2020/04/19/revised PY - 2020/06/08/accepted PY - 2020/6/15/pubmed PY - 2020/6/15/medline PY - 2020/6/15/entrez KW - Echinococcosis KW - Echinococcus granulosus KW - Immunotherapy KW - Masp-2 KW - Nanolipoplexes KW - PD-1 SP - 105579 EP - 105579 JF - Acta tropica JO - Acta Trop. VL - 210 N2 - Cystic echinococcosis (CE), a complex and neglected zoonotic infectious disease, is mainly caused by larval tapeworm Echinococcus granulosus with a worldwide distribution. For CE, an effective drug treatment is not yet available. The present study was conducted to evaluate the efficacy of hMASP-2-based immunotherapy against hydatid cysts by using murine model. Eighteen weeks after infection with 2000 viable protoscoleces intraperitoneally, the infected mice were treated with hMASP-2 DNA nanolipoplexes (pcDNA3.1-hMASP-2) and albendazole respectively. After six weeks treatment, a significant reduction in the weight of cysts was observed both in the pcDNA3.1-hMASP-2 group and albendazole group compared with the untreated group (P < 0.05). The hMASP-2 DNA nanolipoplexes not only inhibited the development of germinal layer, but also induced the extensive degeneration and damage of the germinal layer cells. Furthermore, compared with the untreated group, the number of CD4+T cells and CD8+T cells and the level of serum IFN-γ were significantly increased (P < 0.05). The frequency of PD-1+T-cell subpopulations including CD4+PD-1+T cells and CD8+PD-1+T cells and the level of serum IL-4 were notably decreased (P < 0.05) in the pcDNA3.1-hMASP-2 treatment group. Therefore, the hMASP-2 DNA nanolipoplexes displayed an effective treatment for echinococcosis through inhibiting the development of cysts and up-regulatory T-cell immunity. This new hMASP-2-based immunotherapeutic strategy could be a potential alternative for the treatment of CE, but further studies are recommended to evaluate the full potential of these hMASP-2 DNA nanolipoplexes in the treatment of human CE. SN - 1873-6254 UR - https://www.unboundmedicine.com/medline/citation/32535067/The_immunotherapy_with_hMASP-2_DNA_nanolipoplexes_against_echinococcosis_in_experimentally_protoscolex-infected_mice L2 - https://linkinghub.elsevier.com/retrieve/pii/S0001-706X(19)31735-8 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.